multiple myeloma and other malignancies. Oral Oncol. 2008; 44: 857–869. 7 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing
. Clin. Lymphoma Myeloma Leuk. 2011; 11: 89–92. 4 Treon SP, Tripsas C, Hanzis C, et al. Familial diasease predisposition impacts treatment outcome in patients with Waldenström
–1756. [Hungarian] 11 Pál I, Illés Á, Pál T, et al. Multiple myeloma and secondary tumours. [Myeloma mutiplex és szekunder tumorok.] Hemat Transzf. 2017; 50: 39–42. [Hungarian
1865 1867 Kyle, R. A., Therneau, T. M., Rajkumar, S. V., et al.: Incidence of multiple myeloma in Olmsted county, Minnesota. Trend over 6 decades. Cancer, 2004
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21–33. 25 Alexander DD
994 999 Zamagni, E., Brioli, A. P., Zannetti, B., et al.: Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin. Thromb. Hemost
transplantation for multiple myeloma: risk factors and outcomes. Transpl Infect Dis. 2019; 21: e13052. 12 Satlin MJ, Vardhana S, Soave R, et al. Impact of prophylactic levofloxacin on
−95. [Hungarian] 11 Jakó J, Szerafin L. Epidemiologic features of myeloma in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period. [A myeloma epidemiológiai
-term consequence of PVP in the treatment of metastatic damages of different tumors in the spine, and it has been expanded as an interventional technique to treat spinal osteolytic destruction, multiple myeloma, and painful vertebral compression fractures of
the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24: 945–952. 16 Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to
